The ECHS1 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for investigating short-chain enoyl-CoA hydratase (ECHS1) function in hepatocellular carcinoma models. This product comprises a heterogeneous pool of Huh-7 cells carrying targeted disruptions of the ECHS1 gene, generated through CRISPR/Cas9-mediated gene disruption. The polyclonal format provides a robust loss-of-function model without the clonal artifacts associated with single-cell-derived lines, making it suitable for studying ECHS1-dependent metabolic pathways in a hepatocarcinoma context.
The parental Huh-7 cell line was derived from the hepatocellular carcinoma of a 57-year-old Japanese male and exhibits adherent epithelial morphology. As a widely used model for liver cancer and hepatic metabolism, Huh-7 cells retain key hepatocyte features including expression of metabolic enzymes and responsiveness to nuclear receptor ligands. This cellular background is particularly relevant for dissecting the roles of mitochondrial fatty acid oxidation enzymes such as ECHS1, as the cells are competent for beta-oxidation and mitochondrial respiration, enabling physiologically meaningful metabolic studies.
ECHS1 encodes the mitochondrial enzyme short-chain enoyl-CoA hydratase, which catalyzes the second step of fatty acid beta-oxidation by hydrating short-chain 2-trans-enoyl-CoA to 3-hydroxyacyl-CoA. This reaction is essential for the complete degradation of fatty acids and feeds acetyl-CoA into the TCA cycle for ATP synthesis. ECHS1 activity is transcriptionally regulated by peroxisome proliferator-activated receptors (PPAR??, PPAR??, PPAR??) and is responsive to AMP-activated protein kinase (AMPK) and hypoxia-inducible factor 1-alpha (HIF1A) signaling. The enzyme functions downstream of the carnitine shuttle components CPT1 and CPT2 and interacts with acyl-CoA dehydrogenases (ACADs) and the mitochondrial trifunctional protein subunits HADHA and HADHB. Disruption of ECHS1 impairs the oxidation of short-chain fatty acids, leading to accumulation of 2-trans-enoyl-CoA intermediates, reduced acetyl-CoA production, diminished TCA cycle flux, and increased reactive oxygen species (ROS) levels, ultimately compromising mitochondrial energy homeostasis.
In the Huh-7 hepatocellular carcinoma context, ECHS1 knockout perturbs the metabolic flexibility that supports cancer cell proliferation and survival. Hepatoma cells often rely on fatty acid oxidation as an energy source, and loss of ECHS1 shifts metabolic dependencies, potentially sensitizing cells to metabolic stress. This model recapitulates biochemical hallmarks of short-chain enoyl-CoA hydratase deficiency and Leigh syndrome-like mitochondrial dysfunction, enabling researchers to dissect how defective beta-oxidation contributes to pathophysiology. The polyclonal population averages out clonal variability, providing a consistent phenotype for investigating metabolic reprogramming, oxidative stress responses, and therapeutic vulnerabilities in liver cancer.
Typical applications include metabolic flux analysis using isotopically labeled fatty acids, assessment of mitochondrial function via Seahorse respirometry, acylcarnitine profiling by mass spectrometry, and quantification of cellular ATP and ROS levels. This knockout model is also well-suited for drug screening campaigns targeting mitochondrial dysfunction and for investigating the role of ECHS1 in disease models such as Leigh syndrome and metabolic acidosis. Western blotting, RT-qPCR, and immunofluorescence can be employed to confirm gene disruption and monitor compensatory pathway changes. For additional technical inquiries, please contact Ascent Research.
